AmerisourceBergen Corporation (NYSE:ABC) is a leading provider of drug distribution and other related services designed to reduce healthcare costs and improve patient outcomes. e company lagged after reporting lackluster scal third quarter earnings (ending June) and reducing its revenue guidance for the balance of the year due to brand in ation. In addition, investors were disappointed that AmerisourceBergen held fast to its previously stated view that generic drug pricing will decline in the high single digits and that generic drug de ation is not improving. We, however, remain con dent because of our view that AmerisourceBergen has a superior book of business compared to its peers, remains reasonably attractive from a valuation standpoint, and has several other growth businesses such as animal health.
From Keeley All Cap Value Fund's third quarter 2017 commentary.
